Actively Recruiting
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Led by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Updated on 2025-06-22
500
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.
CONDITIONS
Official Title
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with metastatic breast cancer who underwent a liver, lung, pleural, or bone biopsy in the metastatic setting between January 1, 2005 and January 1, 2024.
You will not qualify if you...
- No available imaging (CT scan and/or PET-FdG scan) within three months before the biopsy or before the last previous treatment interruption.
- Unknown HER2 status.
- Biopsy site is node, soft tissue, or other visceral locations not specified as liver, lung, pleural, or bone.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Istituto Nazionale Tumori
Milan, Italy, 20133
Actively Recruiting
Research Team
C
Claudio Vernieri, MD, PhD
CONTACT
L
Leonardo Provenzano, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here